{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:14:27Z","timestamp":1760300067175},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10689-018-0103-5","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T04:54:24Z","timestamp":1537419264000},"page":"231-239","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Genetic counselling of young women with breast cancer for Li\u2013Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals"],"prefix":"10.1007","volume":"18","author":[{"given":"J. J.","family":"Bakhuizen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Velthuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Stehouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"Bleiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"Ausems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"103_CR1","unstructured":"NABON (2017) Breast cancer, Dutch guideline. \n                    http:\/\/www.oncoline.nl\/borstkanker\n                    \n                  . Accessed 25 May 2018"},{"key":"103_CR2","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL) (2017) Dutch cancer Figs. 2017. \n                    http:\/\/www.cijfersoverkanker.nl\/\n                    \n                  . Accessed 21 May 2018"},{"key":"103_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.genom.9.081307.164339","volume":"9","author":"C Turnbull","year":"2008","unstructured":"Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321\u2013345. \n                    https:\/\/doi.org\/10.1146\/annurev.genom.9.081307.164339","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"13","key":"103_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34(13):1460\u20131468. \n                    https:\/\/doi.org\/10.1146\/annurev.genom.9.081307.164339","journal-title":"J Clin Oncol"},{"issue":"6","key":"103_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/oxfordjournals.aje.a115616","volume":"131","author":"EB Claus","year":"1990","unstructured":"Claus EB, Risch NJ, Thompson D (1990) Age at onset as an indicator of familial risk of breast-cancer. Am J Epidemiol 131(6):961\u2013972. \n                    https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115616","journal-title":"Am J Epidemiol"},{"key":"103_CR6","first-page":"A8910","volume":"159","author":"MA Adank","year":"2015","unstructured":"Adank MA, Hes FJ, van Zelst-Stams WAG et al (2015) CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer. Ned Tijdschr Geneeskd 159:A8910","journal-title":"Ned Tijdschr Geneeskd"},{"key":"103_CR7","unstructured":"National Comprehensive Cancer Network (2018) NCCN Clinical Practice Guidelines in Oncology: genetic\/familial high risk assessment: breast and ovarian (Version I.2018). \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                    \n                   (registration required). Accessed 21 May 2018"},{"key":"103_CR8","unstructured":"Schneider K, Zelley K, Nichols KE et al (1999) Li\u2013Fraumeni syndrome. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews. University of Washington, Seattle. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1311\/\n                    \n                  . Accessed 11 Apr 2013"},{"issue":"9","key":"103_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M et al (2016) TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37(9):865\u2013876. \n                    https:\/\/doi.org\/10.1002\/humu.23035","journal-title":"Hum Mutat"},{"issue":"26","key":"103_CR10","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1200\/JCO.2009.22.7967","volume":"27","author":"J Tinat","year":"2009","unstructured":"Tinat J, Bougeard G, Baert-Desurmont S et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):e108\u2013e109. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.22.7967","journal-title":"J Clin Oncol"},{"issue":"8","key":"103_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ejca.2005.11.032","volume":"42","author":"F Lalloo","year":"2006","unstructured":"Lalloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143\u20131150. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2005.11.032","journal-title":"Eur J Cancer"},{"issue":"8","key":"103_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","volume":"27","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250\u20131256. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.6959","journal-title":"J Clin Oncol"},{"issue":"4","key":"103_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10689-009-9287-z","volume":"8","author":"OM Ginsburg","year":"2009","unstructured":"Ginsburg OM, Akbari MR, Aziz Z et al (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8(4):563\u2013567. \n                    https:\/\/doi.org\/10.1007\/s10689-009-9287-z","journal-title":"Fam Cancer"},{"issue":"12","key":"103_CR14","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1158\/0008-5472.CAN-09-0851","volume":"70","author":"J Mouchawar","year":"2010","unstructured":"Mouchawar J, Korch C, Byers T et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70(12):4795\u20134800. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0851","journal-title":"Cancer Res"},{"issue":"4","key":"103_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10689-012-9557-z","volume":"11","author":"JM McCuaig","year":"2012","unstructured":"McCuaig JM, Armel SR, Novokmet A et al (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11(4):607\u2013613. \n                    https:\/\/doi.org\/10.1007\/s10689-012-9557-z","journal-title":"Fam Cancer"},{"issue":"21","key":"103_CR16","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM et al (2015) Revisiting Li\u2013Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345\u20132352. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.59.5728","journal-title":"J Clin Oncol"},{"key":"103_CR17","unstructured":"Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2005) Erfelijke tumoren: richtlijnen voor diagnostiek en preventie. Edition 2005"},{"key":"103_CR18","unstructured":"Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2010) Erfelijke tumoren: richtlijnen voor diagnostiek en preventie. Edition 2010"},{"key":"103_CR19","unstructured":"Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2017) Erfelijke tumoren: richtlijnen voor diagnostiek en preventie. Edition 2017"},{"key":"103_CR20","unstructured":"Bakhuizen JJ, Hogervorst FB, Velthuizen ME (2018) Early-onset sporadic breast cancer: an indication for routine TP53 germline mutation testing? (manuscript in submission)"},{"key":"103_CR21","unstructured":"UMC Utrecht Julius Centrum (2017) Research online. \n                    http:\/\/www.researchonline.info\n                    \n                  . Accessed 7 May 2017"},{"key":"103_CR22","unstructured":"Stichting Diagnose Kanker (SDK), European Li\u2013Fraumeni Families Foundation (ELFF) (2014) Zorgstandaard Li\u2013Fraumeni Syndroom. Edition 2014. \n                    http:\/\/www.zorginzicht.nl\/bibliotheek\/ll-fraumeni-syndroom\/KwaliteitsstandaardenDocumenten\/Zorgstandaard-li-fraumeni.pdf\n                    \n                  . Accessed 10 May 2017"},{"issue":"5","key":"103_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","volume":"11","author":"KA McBride","year":"2014","unstructured":"McBride KA, Ballinger ML, Killick E et al (2014) Li\u2013Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11(5):260\u2013271. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2014.41","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"103_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li\u2013Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559\u2013567. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(11)70119-X","journal-title":"Lancet Oncol"},{"issue":"9","key":"103_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li\u2013Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17(9):1295\u20131305. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30249-2","journal-title":"Lancet Oncol"},{"issue":"11","key":"103_CR26","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz CP, Achatz MI, Brugieres L et al (2017) Cancer screening recommendations for individuals with Li\u2013Fraumeni syndrome. Clin Cancer Res 23(11):e38\u2013e45. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0408","journal-title":"Clin Cancer Res"},{"issue":"12","key":"103_CR27","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1001\/jamaoncol.2017.1346","volume":"3","author":"MWG Ruijs","year":"2017","unstructured":"Ruijs MWG, Loo CE, van Buchem CAJM, et al (2017) Surveillance of Dutch patients with Li\u2013Fraumeni syndrome: the LiFe-Guard Study. JAMA Oncol 3(12):1733\u20131734. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2017.1346","journal-title":"JAMA Oncol"},{"issue":"8","key":"103_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pon.1352","volume":"17","author":"SK Peterson","year":"2008","unstructured":"Peterson SK, Pentz RD, Marani SK et al (2008) Psychological functioning in persons considering genetic counseling and testing for Li\u2013Fraumeni syndrome. Psychooncology 17(8):783\u2013789. \n                    https:\/\/doi.org\/10.1002\/pon.1352","journal-title":"Psychooncology"},{"issue":"18","key":"103_CR29","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2009.27.2112","volume":"28","author":"CR Lammens","year":"2010","unstructured":"Lammens CR, Aaronson NK, Wagner A et al (2010) Genetic testing in Li\u2013Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008\u20133014. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.2112","journal-title":"J Clin Oncol"},{"issue":"6","key":"103_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/pon.1951","volume":"20","author":"CR Lammens","year":"2011","unstructured":"Lammens CR, Bleiker EM, Verhoef S et al (2011) Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology 20(6):631\u2013638. \n                    https:\/\/doi.org\/10.1002\/pon.1951","journal-title":"Psychooncology"},{"key":"103_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1472-6963-9-160","volume":"9","author":"JV Cook","year":"2009","unstructured":"Cook JV, Dickinson HO, Eccles MP (2009) Response rates in postal surveys of healthcare professionals between 1996 and 2005: an observational study. BMC Health Serv Res 9:160. \n                    https:\/\/doi.org\/10.1186\/1472-6963-9-160","journal-title":"BMC Health Serv Res"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-018-0103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-018-0103-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-018-0103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:10:28Z","timestamp":1568920228000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-018-0103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s10689-018-0103-5","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"20 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Medical Research Ethical Committee concluded that the Medical Research Human Subject Acts (WMO) does not apply.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}